Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study

Table 1 Characteristics of JDM patients and HC at study inclusion

	JDM (n = 47)	HC (n = 41)	p-value^c
First qHPV vaccine dose between 9 to 13 years, n (%)	20 (42.6)	9 (22.0)	0.045
First qHPV vaccine dose between 14 to 20 years, n (%)	27 (57.4)	32 (78.0)	0.045
First qHPV vaccine dose, median age in years (IQR)	16 (13.0–19.0)	14 (6.5–21.5)	0.001
Diagnosis, median age in years (IQR)	7 (0–14.5)	NA	NA
1 dose previous to the study, n (%)	4 (8.5)	2 (4.9)	1.000
2 doses previous to the study, n (%)	1 (2.1)	0 (0.0)	1.000
Sexual activity initiation, n (%)	9 (19.1)	11 (26.8)	0.450
Immunossupressive medications use, n (%)	35 (74.5)	NA	NA
JDM group A^a, n (%) [median CMAS]	12 (25.5) [52]	NA	NA
JDM group B^a, n (%) [median CMAS]	17 (36.2) [52]	NA	NA
JDM group C^a, n (%) [median CMAS]	18 (38.3) [37]	NA	NA
	JDM (n = 37)	HC (n = 39)	p-value^c
Seropositivity for HPV 16, n (%)	10 (27.0)^b	2 (5.1)	0.011
Seropositivity for HPV 18, n (%)	9 (24.3)^b	1 (2.6)	0.006

JDM juvenile dermatomyositis, HC healthy controls, HPV human papillomavirus, qHPV quadrivalent HPV vaccine, NA not applicable, CMAS childhood myositis activity score, IQR interquartile range
^aJDM groups: A = inactive disease without medication; B = inactive disease with medication; C = active disease with medication. Considering active disease: CMAS < 48 or MMT < 78 or unsatisfactory physician global assessment of overall disease activity (PhyGloVAS)
^bSix patients were seropositive for both HPV16 and 18, four were seropositive only for HPV16, and three only for HPV18
^cStatistical significance was defined as a p-value < 0.05

ISSN: 1546-0096